Colon and Rectal Cancer Drugs Market 2021 Statistical Analysis, Key Segments, Benefits and Opportunity and Forecast 2030
Colon and rectal cancers are frequently lumped together because they share many characteristics. Colorectal cancer is becoming more common among millennials in the United States. According to the American Cancer Society (ACS), there will be approximately 97,220 new cases of colon cancer and approximately 43,030 new cases of rectal cancer registered in the United States in 2018. Furthermore, due to the rising risk of Colon and Rectal Cancer Drugs Market, the American Cancer Society (ACS) updated its colorectal cancer screening guidelines in May 2018, recommending that colorectal cancer screening begins at the age of 45 rather than 50.
Drivers of the Colon and Rectal Cancer Drugs Market
The rising incidence and prevalence of colon and rectal cancer around the world, as well as increased research and development studies for colorectal cancer treatment, are expected to drive Growth in The Colon and Rectal Cancer Drugs Market in the near future. According to the American Cancer Society (ACS) data from February 2018, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States.
Furthermore, the Centers for Disease Control and Prevention (CDC) reported that in 2014, approximately 139,992 people in the United States were diagnosed with colorectal cancer, including 73,396 men and 66,596 women. Colorectal cancer claimed the lives of approximately 51,651 people in the United States, including 27,134 men and 24,517 women. Furthermore, according to World Health Organization (WHO) data from 2012, colorectal cancer is the third most common cancer in men (746,000 cases, 10.0 percent of the total) and the second most common cancer in women (614,000 cases, 9.2 percent of the total) worldwide.
Furthermore, approximately 55% of these cases occurred in developed regions. The growing number of R&D studies conducted by government and private healthcare organizations is also fueling the growth of the Colon and Rectal Cancer Drugs Market. For example, until March 2018, the American Cancer Society (ACS) spent US$ 54 million on colon and rectal cancer research through 92 research grants.
Comments
Post a Comment